Sanofi‘s patent includes antigenic respiratory syncytial virus (RSV) polypeptides designed to elicit antibodies against RSV. The claim specifies a glycosylated RSV F polypeptide that blocks a shared epitope, with a sequence closely related to a defined reference, enhancing its potential for immunological applications. GlobalData’s report on Sanofi gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Sanofi, NSAID cancer drugs was a key innovation area identified from patents. Sanofi's grant share as of July 2024 was 62%. Grant share is based on the ratio of number of grants to total number of patents.
Rsv polypeptides for antibody elicitation against respiratory syncytial virus
The granted patent US12071454B2 outlines a series of claims related to antigenic polypeptides derived from the respiratory syncytial virus (RSV), specifically focusing on the RSV F protein. The claims detail polypeptides that include glycosylated asparagine residues at specific positions, which serve to block epitopes shared between pre-fusion and post-fusion forms of the RSV F protein. The polypeptides are characterized by a high degree of sequence identity to established sequences (SEQ ID NO: 23 and SEQ ID NO: 26) and include variations that may enhance their immunogenic properties. Notably, the claims also encompass combinations of RSV F polypeptides with ferritin proteins, which may include specific mutations to improve their efficacy as immunogens.
Additionally, the patent claims cover methods for eliciting an immune response against RSV by administering these antigenic polypeptides to subjects, as well as the potential for compositions that combine RSV F polypeptides with other viral components, such as RSV G polypeptides. The inclusion of ferritin particles and immune-stimulatory moieties linked to the ferritin further suggests a strategy to enhance the immune response. The claims also specify the absence of a furin cleavage site in certain polypeptides, indicating a focus on stability and functionality in vaccine development. Overall, the patent presents a comprehensive approach to developing RSV vaccines through innovative modifications of viral proteins.
To know more about GlobalData’s detailed insights on Sanofi, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
